Trial Profile
Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jul 2015
Price :
$35
*
At a glance
- Drugs Bupropion (Primary) ; Nicotine (Primary) ; Varenicline (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 20 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.